• Fernández de LarreaCarlosCDepartment of Hematology, Hospital Clínic, Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Spain., Natalia Tovar, María Rozman, Laura Rosiñol, Juan Ignacio Aróstegui, María Teresa Cibeira, Montserrat Rovira, Jordi Yagüe, and Joan Bladé.
• Department of Hematology, Hospital Clínic, Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Spain.
• Biol. Blood Marrow Transplant. 2011 Jul 1; 17 (7): 1084-7.

AbstractThe current definition of complete remission (CR) in multiple myeloma (MM) requires a negative serum and urine immunofixation (IFE) and <5% bone marrow plasma cells (BMPCs). The aim of this study was to determine the value of BMPCs count by standard microscopic evaluation in patients with MM in serologic CR after autologous stem cell transplantation (ASCT). Thirty-five patients with a median follow-up after ASCT of 7.3 years were studied. The percentage of BMPCs was an independent predictor of progression in multivariate model (hazard ratio 2.02, P = .009). Patients with >1.5% BMPCs (median: 0.8%) after ASCT had an increased risk of progression (P = .016) and a trend toward a shorter survival (P = .195). In conclusion, conventional morphology of bone marrow is a useful and rapid tool as a first step to assess the residual tumor mass in patients with MM in CR after ASCT, and it constitutes a strong predictor for disease progression.2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

38 keywords...

hide…